M2 Pharma - Therapy Areas

Elicera Therapeutics secures Chinese patent allowance for ELC-401

5 November 2026 - Swedish clinical stage immuno-oncology company Elicera Therapeutics AB (STO: ELIC) on Thursday said the China National Intellectual Property Administration has issued a notice of all...

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

4 November 2026 - Swedish precision oncology company CHOSA Oncology AB (Spotlight Stock Market: CHOSA) said on Wednesday it has signed an agreement with a CLIA-certified laboratory to develop and vali...

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

4 November 2026 - Oncology company BeOne Medicines Ltd (Nasdaq: ONC) (HKEX: 06160) (SSE: 688235) reported on Wednesday that it has received US Food and Drug Administration (FDA) Priority Review for it...

Pentixapharm advances preparationsfor Phase 3 PANDA study

4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval ...

CStone and Kimia Therapeutics collaborate to advance oncology drug candidate

4 November 2026 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Tuesday that it has entered into a clinical collaboration agreement with US-based Kimia Therapeutics...

Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia

3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) f...